Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP911078.RAQwQj2INwcchtfm2FC4BpzIO7Bq9rSafiv43iU6pR9Jk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP911078.RAQwQj2INwcchtfm2FC4BpzIO7Bq9rSafiv43iU6pR9Jk130_assertion type Assertion NP911078.RAQwQj2INwcchtfm2FC4BpzIO7Bq9rSafiv43iU6pR9Jk130_head.
- NP911078.RAQwQj2INwcchtfm2FC4BpzIO7Bq9rSafiv43iU6pR9Jk130_assertion description "[We retrospectively studied four cases of t-MDS/AML among 210 (1.9%) consecutive patients with CLL treated at a single center with fludarabine and cyclophosphamide (FC) either as the first- or second-line therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP911078.RAQwQj2INwcchtfm2FC4BpzIO7Bq9rSafiv43iU6pR9Jk130_provenance.
- NP911078.RAQwQj2INwcchtfm2FC4BpzIO7Bq9rSafiv43iU6pR9Jk130_assertion evidence source_evidence_literature NP911078.RAQwQj2INwcchtfm2FC4BpzIO7Bq9rSafiv43iU6pR9Jk130_provenance.
- NP911078.RAQwQj2INwcchtfm2FC4BpzIO7Bq9rSafiv43iU6pR9Jk130_assertion SIO_000772 21775097 NP911078.RAQwQj2INwcchtfm2FC4BpzIO7Bq9rSafiv43iU6pR9Jk130_provenance.
- NP911078.RAQwQj2INwcchtfm2FC4BpzIO7Bq9rSafiv43iU6pR9Jk130_assertion wasDerivedFrom befree-2016 NP911078.RAQwQj2INwcchtfm2FC4BpzIO7Bq9rSafiv43iU6pR9Jk130_provenance.
- NP911078.RAQwQj2INwcchtfm2FC4BpzIO7Bq9rSafiv43iU6pR9Jk130_assertion wasGeneratedBy ECO_0000203 NP911078.RAQwQj2INwcchtfm2FC4BpzIO7Bq9rSafiv43iU6pR9Jk130_provenance.